3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
pembrolizumab
25
Cisplatin
24
Carboplatin
19
Paclitaxel
16
Magnetic Resonance Spectroscopy
16
Specimen Handling
14
Pemetrexed
12
durvalumab
10
Radiotherapy, Intensity-Modulated
8
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Nivolumab
7
Radiation
6
Docetaxel
6
Cetuximab
6
Biopsy
6
osimertinib
5
cemiplimab
5
Taxes
5
Radiotherapy
5
Ipilimumab
5
Gemcitabine
5
Cyclophosphamide
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
poly ICLC
4
cabozantinib
4
atezolizumab
4
Oxaliplatin
4
Fluorouracil
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Nimorazole
×
1 year
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled